InSphero is a cutting-edge biotechnology startup that specializes in developing advanced 3D cell culture models and organ-on-a-chip technology. These innovative solutions are designed to mimic human tissue and organ functions, providing researchers with more accurate and reliable data for drug testing and disease research. The company primarily serves pharmaceutical and biotechnology companies, academic institutions, and research organizations focused on complex diseases such as diabetes, cancer, and liver diseases.

Operating in the biomedical research market, InSphero offers a range of products and services that include 3D microtissue models, specially formulated media, and optimized assay protocols. Their technology allows for the creation of physiologically relevant models that can replicate human disease progression and tissue interactions more accurately than traditional 2D cell cultures. This leads to better predictive data for drug efficacy and safety, ultimately accelerating the drug development process.

InSphero's business model revolves around selling their 3D cell culture products and providing specialized testing services. They generate revenue by offering these products and services to their clients, who rely on InSphero's expertise to conduct high-quality, reproducible experiments. Additionally, the company offers expert support from experienced application scientists and the option to outsource testing to their services team, providing a comprehensive solution for their clients' research needs.

By focusing on innovation and quality, InSphero ensures that their microtissue models meet stringent standards, such as the EN ISO 9001 Quality System. This commitment to excellence has made them a trusted partner for leading pharmaceutical companies and research institutions worldwide.

Keywords: 3D cell culture, organ-on-a-chip, drug testing, biomedical research, microtissue models, pharmaceutical, biotechnology, disease research, drug development, innovation.